Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human, Monkey (tested or 100% immunogen sequence identity)
IHC - Paraffin (10 µg/ml)
Specificity and Use
VIPR1 antibody was raised against synthetic 16 amino acid peptide from 3rd cytoplasmic domain of human VIP Receptor 1. Percent identity with other species by BLAST analysis: Human, Gorilla, Gibbon, Monkey (100%); Marmoset, Elephant, Rabbit (88%); Mouse, Rat, Bovine, Guinea pig (81%).
VIPR1 Antibody, HVR1 Antibody, PACAP type II receptor Antibody, PACAP-R-2 Antibody, Pvr2 Antibody, RDC1 Antibody, Vip receptor subtype 1 Antibody, Vpac1 receptor Antibody, V1RG Antibody, VIP receptor 1 Antibody, VIPR Antibody, VIRG Antibody, VPCAP1R Antibody, PACAP-R2 Antibody, VAPC1 Antibody, VIP and PACAP receptor 1 Antibody, VPAC1R Antibody, Pacap receptor, type ii Antibody, Type II PACAP receptor Antibody, VIP receptor, type I Antibody, VIP-R-1 Antibody, VIP1 receptor Antibody, VPAC1 Antibody
Vasoactive Intestinal Polypeptide Receptor 1 (VIPR1) is a member of the Vasoactive Intestinal Polypeptide subfamily. Vasoactive intestinal peptide (VIP) plays multiple roles in the nervous, endocrine, and immune systems as a neurotransmitter, a hormone, and a cytokine. VIPR1, a receptor for VIP, has been shown to expressed widely in normal tissues and is the predominant receptor subtype for VIP in cancers.